Education
About Us
Working with TipRanks
Follow Us
XWELL (XWEL)
NASDAQ:XWEL
Top Page
XWELL
(NASDAQ:XWEL)
49Neutral
XWELL (XWEL) vs. S&P 500 (SPY)
Market Cap
$5.37M
Dividend YieldN/A
Average Volume (3M)69.47K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth11.79%
EPS Growth56.19%
CountryUS
Employees266
SectorHealthcare
Sector Strength65
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)-3.64
Shares Outstanding5,261,024
10 Day Avg. Volume119,408
30 Day Avg. Volume69,466
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.16
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
XWELL Business Overview & Revenue Model
Company DescriptionXWELL (XWEL) is a company that operates within the wellness and health sectors, providing a range of services and products designed to enhance the well-being and comfort of its customers. The company is known for its innovative approach to health and wellness, offering solutions that cater to the modern lifestyle needs of its clients.
How the Company Makes MoneyXWELL generates revenue through a diversified model that includes offering wellness and health-related services at various locations, potentially including spas, lounges, or specialized health facilities. These services may include treatments, therapies, and other wellness programs designed to meet the needs of its clientele. Additionally, XWELL might engage in partnerships with other businesses or brands to expand its reach and enhance its service offerings, thereby contributing to its overall earnings. The company's revenue streams are likely supported by consumer demand for enhanced wellness experiences and its ability to cater to a broad audience seeking health and relaxation solutions.
XWELL Financial Statement Overview
Summary
XWELL's financial performance is challenged by consistent net losses and negative cash flows, despite revenue growth and improved gross profit margins. The high leverage and declining equity present financial stability risks.Income Statement
XWELL's revenue showed a positive growth from 2023 to TTM, indicating a recovery trajectory. However, the company has consistently operated at a net loss, with negative net and EBIT margins, reflecting ongoing profitability challenges. The gross profit margin improved slightly, which is a positive sign, but overall profitability remains a concern.45
Neutral
Balance Sheet
The debt-to-equity ratio has increased as equity declined, indicating higher financial leverage and potential risk. Stockholders’ equity has been decreasing, impacting the equity ratio negatively. Return on equity is concerning due to continuous net losses, which may affect future financial stability.38
Negative
Cash Flow
Free cash flow has improved slightly in TTM compared to 2023, but remains negative, indicating ongoing cash management challenges. The operating cash flow to net income ratio is negative, reflecting difficulties in converting profits into cash flow. The company needs to enhance operational efficiency to improve cash flow metrics.42
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 33.83M | 30.11M | 55.94M | 73.73M | 8.38M | 48.52M | Gross Profit |
| 8.16M | 3.68M | 12.05M | 32.43M | -3.60M | 10.66M | EBIT |
| -13.01M | -19.30M | -24.55M | 5.87M | -40.10M | -9.78M | EBITDA |
| -11.78M | -15.75M | -19.12M | 7.87M | -19.54M | -11.24M | Net Income Common Stockholders |
| -15.84M | -27.74M | -32.63M | 3.35M | -92.23M | -20.53M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.44M | 23.05M | 42.19M | 105.51M | 89.80M | 2.18M | Total Assets |
| 1.99M | 38.99M | 70.43M | 127.27M | 103.13M | 28.72M | Total Debt |
| 3.20M | 11.09M | 14.11M | 13.82M | 15.38M | 15.26M | Net Debt |
| 1.77M | 2.66M | -4.93M | -91.68M | -74.42M | 13.07M | Total Liabilities |
| 20.30M | 18.02M | 22.48M | 27.33M | 22.76M | 31.26M | Stockholders Equity |
| -18.31M | 13.00M | 39.93M | 92.73M | 77.81M | -6.24M |
| Cash Flow | Free Cash Flow | ||||
| -12.07M | -18.45M | -31.02M | 6.97M | -29.36M | -2.39M | Operating Cash Flow |
| -10.74M | -16.07M | -24.19M | 15.64M | -25.01M | -113.00K | Investing Cash Flow |
| 9.01M | 5.65M | -34.84M | -6.24M | -4.35M | -2.27M | Financing Cash Flow |
| 1.36M | 8.00K | -27.38M | 6.35M | 117.22M | 1.17M |
XWELL Technical Analysis
Negative
0.99
Price Trends
1.11
Negative
1.31
Negative
1.57
Negative
Market Momentum
-0.02
Negative
44.81
Neutral
34.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.01, below the 50-day MA of 1.11, and below the 200-day MA of 1.57, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 44.81 is Neutral, neither overbought nor oversold. The STOCH value of 34.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XWEL.
XWELL Risk Analysis
XWELL disclosed 52 risk factors in its most recent earnings report. XWELL reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XWELL Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $5.37M | ― | -123.26% | ― | 11.79% | 56.19% | |
48 Neutral | $6.86B | 1.11 | -51.04% | 2.47% | 16.66% | 1.53% | |
43 Neutral | $7.40M | ― | -18.06% | ― | -30.19% | 75.92% | |
38 Underperform | $2.65M | ― | -108.57% | ― | -100.00% | 6.87% | |
37 Underperform | $1.94M | ― | -100.40% | ― | -58.46% | 47.98% | |
36 Underperform | $3.58M | ― | -385.90% | ― | -65.44% | 96.80% |
* Healthcare Sector Average
Performance Comparison
XWEL
XWELL
0.99
-0.49
-33.11%
XXII
22nd Century
1.51
-261.74
-99.43%
APDN
Applied DNA Sciences
1.68
-427.32
-99.61%
MTNB
Matinas BioPharma
0.57
-16.93
-96.74%
AYTU
Aytu BioScience
1.16
-1.87
-61.72%
XWELL Earnings Call Summary
Earnings Call Date: Mar 27, 2025 | % Change Since: -9.17% | Next Earnings Date: May 19, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.Highlights
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Strategic Expansion Plans
Planning to expand into several attractive markets in Florida, with up to 10 XWELL properties expected by mid-2025. Opening first Naples Wax location in November 2024.
Successful Cost Reduction
Reduced total operating expenses by approximately 35% for the 9-month period in 2024 compared to the same period in 2023.
Decrease in Operating Loss
Operating loss for Q3 2024 was $4.8 million, a significant improvement from an operating loss of $12.1 million in the prior year third quarter.
Solid Financial Position
No long-term debt with cash and cash equivalents at $4.4 million and $11.7 million in marketable securities.
Positive Customer Engagement
Customer traction and foot traffic at the new Philadelphia International Airport XpresSpa have been solid, with promising performance from tech-forward installations.
Lowlights
Increased Salaries and Benefits
Salaries and benefits were approximately $1.9 million in Q3 2024, compared to $1.2 million in the same period in 2023.
Legal Expenses Impact
General and administrative expenses were approximately $4.5 million, including over $2 million related to extraordinary legal expenses.
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.XWELL Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
XWELL Announces Key Leadership Appointments for Growth
Positive
Jan 7, 2025
XWELL, Inc. announced new senior leadership appointments to support its strategic growth and business objectives. Ian Brown has been appointed as the new Chief Financial Officer, succeeding Suzanne Scrabis, and is granted stock options as part of his inducement to join. Peter Vermeulen and Mike Heronime have also joined as the new head of Human Resources and Marketing Director, respectively, on a fractional basis. These appointments are expected to enhance XWELL’s brand unification, company culture, and financial and operational performance.
Product-Related AnnouncementsBusiness Operations and Strategy
XWELL Unifies Wellness Offerings to Boost Growth
Positive
Dec 5, 2024
XWELL Inc. is embarking on a transformative journey to unify its wellness offerings under a single brand, aiming to capitalize on the booming wellness industry. The company plans to enhance customer engagement through AI-driven health solutions and expand its footprint beyond airports with new retail centers. By integrating innovative self-service options and loyalty programs, XWELL is set to provide accessible wellness experiences, driving growth and shareholder value.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.